Tremor

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Retrieved on: 
Monday, March 25, 2024
Toxicity, Nephrotoxicity, Transplant, Organ transplantation, Central nervous system, Risk, Patient, Kidney transplantation, Tacrolimus, Thumbay Hospital, Life, Kidney, Immune system, Tremor, Hypertension, Immunosuppressive drug

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.

Key Points: 
  • IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • In transplantation procedures, organ rejection is a major cause of graft failure, which can be a life-threatening condition.
  • Rejection occurs due to allorecognition, wherein the recipient's immune system identifies the transplanted organ as foreign tissue, triggering an immune response against the transplanted organ.
  • Calcineurin inhibitors (“CNIs”) are a critical component of most immunosuppressive regimens to prevent acute and long-term organ transplant rejection.

MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Surgery, Hospitals, FDA, Health Technology, Hardware, Robotics, Health, Oncology, Freedom, Surgeon, Classification, Lymphedema, Filtration, Physician, Patient, Hospital, European, Platform supply vessel, Tremor, Blood, Wrist, Hand, Microsurgery, Food, Medicine, Dentistry

The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.

Key Points: 
  • The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.
  • “With the authorization from the FDA, our technology will expand its reach to pioneering hospitals in the U.S.
  • The Symani Surgical System provides advanced solutions for a range of open surgeries, including post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer, and lymphatic system repair.
  • MMI plans to immediately launch the technology in the U.S.
    To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com .

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, PDQ, Depression, Parkinson's disease, Disease, Sleep, Patient, URMC, Research, Anxiety, University, Telehealth, Hope, Quality of life, Eye, Chet, Light, Clinical trial, Retina, Cognition, MDS, Tremor, Fatigue, FDA, The, Pharmaceutical industry

The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.

Key Points: 
  • The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.
  • This pivotal trial will assess the efficacy of Celeste®, the company’s FDA Breakthrough phototherapy device to improve non-motor and motor function and quality of life in Parkinson’s disease (PD).
  • This 300-patient phototherapy trial will be the largest trial of its kind.
  • “A pivotal trial for medical devices is similar to a phase 3 trial drug trial,” said Dan Adams, chief science officer.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Professional Services, Health, Philanthropy, Pharmaceutical, Other Science, Research, Fund Raising, Genetics, Science, Finance, PD, Dopaminergic, Partnership, Neuron, Amnesia, Culture, TF, DSM-IV codes, Tremor, MJFF, Speed, Depression

bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
  • Under the terms of the collaboration agreement, both wild type human cells and physiologically relevant disease model cells can be generated through individual project agreements.
  • “We are thrilled to partner with bit.bio and to leverage the company’s unique platform for the generation of human cells.

People with Essential Tremor May Have Increased Risk of Dementia

Retrieved on: 
Wednesday, March 6, 2024
Head, Master of Science, Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Arm, Physician, Thought, Stroke, Tremor, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Prevalence, Multiple sclerosis, Parkinson's disease, Human, University, Essential tremor, Movement disorder, Dementia, Eating, Concussion, Epilepsy, Diagnosis, Brain, Research, Jaw, American Academy, Pharmaceutical industry

Essential tremor is the most common tremor disorder, more common than Parkinson's disease.

Key Points: 
  • Essential tremor is the most common tremor disorder, more common than Parkinson's disease.
  • "Not only do tremors affect a person's ability to complete daily tasks such writing and eating, our study suggests that people with essential tremor also have an increased risk of developing dementia."
  • The study involved 222 people with essential tremor who had an average age of 79 at the start of the study.
  • "While the majority of people with essential tremor will not develop dementia, our findings provide the basis for physicians to educate people with essential tremor and their families about the heightened risk, and any potential life changes likely to accompany this diagnosis," Louis said.

INSIGHTEC FOCUSED ULTRASOUND NOW COVERED FOR PARKINSON'S DISEASE PALLIDOTOMY IN US

Retrieved on: 
Monday, February 26, 2024
Quality of life, High-intensity focused ultrasound, Blue Shield, DSM-IV codes, Hope, Tremor, Elevance Health, Safety, Parkinson's disease, Anesthesia, BCBS, Neuro, Insurance, Health insurance

HAIFA, Israel and MIAMI, Feb. 26, 2024 /PRNewswire/ -- Anthem Blue Cross and Blue Shield (BCBS) has become the first insurance provider to extend coverage for the innovative focused ultrasound pallidotomy procedure as part of their comprehensive Parkinson's disease treatment coverage. This decision brings hope and relief to more than 1 million Americans living with Parkinson's who now have greater access to an incisionless treatment alternative, when medications have been unsuccessful or have resulted in intolerable side effects.

Key Points: 
  • Insightec, a global leader in focused ultrasound, developed the pioneering treatment that uses MR-guided focused ultrasound (MRgFUS) to destroy a small area of brain tissue involved in the motor symptoms of Parkinson's.
  • "Parkinson's disease is the second-most common neurodegenerative disorder in the US, affecting as many as 1 million Americans," continues Dee Kolanek, VP of Market Access and Reimbursement for Insightec.
  • "By offering coverage reimbursement for focused ultrasound pallidotomy, Anthem BCBS is demonstrating its leadership in the industry, as well as their commitment to the well-being of their members and a significant patient population."
  • For additional information about Anthem Blue Cross and Blue Shield and the specific qualifications of coverage for the Insightec focused ultrasound thalamotomy procedure, please contact their member services or visit their official website .

VAULT RELEASES 2024 RANKINGS OF BEST CONSULTING FIRMS TO WORK FOR IN EMEA AND APAC REGIONS

Retrieved on: 
Wednesday, February 21, 2024
SVP, Culture, Consultant, AWR, Most, Uncertainty, Tremor, Bain & Company

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Vault, the leader in data-driven employer rankings and verified employee reviews, today released its 2024 rankings of the Best Consulting Firms to Work For in the Europe, Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions. These rankings recognize the leading firms in more than 70 categories, including the Best Consulting Firms to Work For in EMEA and APAC. For each region, Vault also ranks the Most Prestigious Consulting Firms, Best Consulting Firms by Practice Area, and Best Consulting Firms by Employment Factor.

Key Points: 
  • These rankings recognize the leading firms in more than 70 categories, including the Best Consulting Firms to Work For in EMEA and APAC.
  • For each region, Vault also ranks the Most Prestigious Consulting Firms, Best Consulting Firms by Practice Area, and Best Consulting Firms by Employment Factor.
  • Munich-based Roland Berger took the #2 spot behind Bain & Company in the Best Consulting Firms to Work for in EMEA.
  • Smaller, regionally focused firms are also among the Best Consulting Firms to Work For in EMEA and APAC.

MHI Group Presents "Best Innovation 2023" Awards for Activities that Contribute to Protecting the Environment

Retrieved on: 
Wednesday, February 21, 2024
Hydrogen, Filtration, Energy, Toxicity, Tokyo Institute of Technology, LCC, Noto Peninsula, Tremor, CCUS, Engineering, Innovation Center station, LPG, PTFE, Polytetrafluoroethylene, Transport, Engineering Division, Mitsubishi Heavy Industries, Pressure, MHI, HBF, Dioxin, Kyoto University, Carbon, Chemical engineering, Incineration, Taisei Corporation, CO2, Knowledge, Primetals Technologies, Temperature, Logistics, Works, LNG, Government, GTCC, BOG, Renewable energy

Through this in-house program, the Company aims to raise environmental awareness and encourage further innovation among its groupwide employees.

Key Points: 
  • Through this in-house program, the Company aims to raise environmental awareness and encourage further innovation among its groupwide employees.
  • An anchorless construction method enables easy equipment installation and layout changes-, a feature that has brought accolades from multi-tenant warehouse owners.
  • By utilizing knowledge and expertise of MHI group, a "liquefied CO2 handling system" enabling transport of liquefied CO2 in large volumes is being developed.
  • In these ways, MHI Group has been making its initiatives toward realizing a carbon neutral society widely known.